Ocular complications after antivascular endothelial growth factor therapy in medicare patients with age-related macular degeneration

  • S. D
  • K. A
  • P. M
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

To determine longitudinal rates of ocular complications after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD) in a nationally representative longitudinal sample. Retrospective, longitudinal case-control study. Using the Medicare 5% claims database, diagnoses of neovascular AMD and anti-VEGF injections of ranibizumab, bevacizumab, or pegaptanib were identified from International Classification of Diseases and Current Procedural Terminology procedure codes. Six thousand one hundred fifty-four individuals undergoing anti-VEGF treatment for neovascular AMD (total of 40 903 injections) were compared with 6154 matched controls with neovascular AMD who did not undergo anti-VEGF treatment. Propensity score matching was used to match individuals receiving anti-VEGF injections with controls. Rates of postinjection adverse outcomes (endophthalmitis, rhegmatogenous retinal detachment, retinal tear, uveitis, and vitreous hemorrhage) were analyzed by cumulative incidence and Cox proportional hazards model to control for demographic factors and ocular comorbidities. At the 2-year follow-up, the rates of endophthalmitis per injection (0.09%; P

Author-supplied keywords

  • *Angiogenesis Inhibitors/tu [Therapeutic Use]
  • *Eye Diseases/et [Etiology]
  • *Intravitreal Injections/ae [Adverse Effects]
  • *Macular Degeneration/dt [Drug Therapy]
  • *Medicare Part B/sn [Statistics & Numerical Data]
  • *Vascular Endothelial Growth Factor A/ai [Antagoni
  • *angiogenesis inhibitor/dt [Drug Therapy]
  • *bevacizumab/ae [Adverse Drug Reaction]
  • *bevacizumab/dt [Drug Therapy]
  • *endothelial cell growth factor
  • *eye disease/di [Diagnosis]
  • *eye disease/ep [Epidemiology]
  • *eye disease/et [Etiology]
  • *human
  • *intravitreal drug administration/ae [Adverse Drug
  • *medicare
  • *patient
  • *pegaptanib/ae [Adverse Drug Reaction]
  • *pegaptanib/dt [Drug Therapy]
  • *ranibizumab/ae [Adverse Drug Reaction]
  • *ranibizumab/dt [Drug Therapy]
  • *retina macula age related degeneration
  • *retina macula age related degeneration/co [Compli
  • *retina macula age related degeneration/dt [Drug T
  • *retina macula degeneration/dt [Drug Therapy]
  • *therapy
  • *vasculotropin A
  • 80 and over
  • Aged
  • Antibodies
  • Aptamers
  • Bevacizumab
  • Case-Control Studies
  • Endophthalmitis/di [Diagnosis]
  • Endophthalmitis/ep [Epidemiology]
  • Endophthalmitis/et [Etiology]
  • Eye Diseases/di [Diagnosis]
  • Eye Diseases/ep [Epidemiology]
  • Female
  • Follow-Up Studies
  • Health Services Research
  • Humanized
  • Humans
  • Incidence
  • International Classification of Diseases
  • Male
  • Monoclonal
  • Monoclonal/ae [Adverse Effects]
  • Nucleotide/ae [Adverse Effects]
  • Proportional Hazards Models
  • Ranibizumab
  • Retinal Detachment/di [Diagnosis]
  • Retinal Detachment/ep [Epidemiology]
  • Retinal Detachment/et [Etiology]
  • Retinal Perforations/di [Diagnosis]
  • Retinal Perforations/ep [Epidemiology]
  • Retinal Perforations/et [Etiology]
  • Retrospective Studies
  • United States
  • Uveitis/ci [Chemically Induced]
  • Uveitis/di [Diagnosis]
  • Uveitis/ep [Epidemiology]
  • VEGFA protein
  • Vitreous Hemorrhage/di [Diagnosis]
  • Vitreous Hemorrhage/ep [Epidemiology]
  • Vitreous Hemorrhage/et [Etiology]
  • adverse outcome
  • aged
  • aptamer/ae [Adverse Drug Reaction]
  • article
  • bevacizumab
  • case control study
  • chemically induced disorder
  • comorbidity
  • control group
  • controlled study
  • data base
  • diagnosis
  • drug antagonism
  • endophthalmitis
  • endophthalmitis/di [Diagnosis]
  • endophthalmitis/ep [Epidemiology]
  • endophthalmitis/et [Etiology]
  • endophthalmitis/si [Side Effect]
  • female
  • follow up
  • hazard
  • health services research
  • human
  • incidence
  • injection
  • longitudinal study
  • major clinical study
  • male
  • medical information system
  • model
  • monoclonal antibody/ae [Adverse Drug Reaction]
  • neovascularization (pathology)
  • pegaptanib
  • priority journal
  • propensity score
  • proportional hazards model
  • ranibizumab
  • retina detachment
  • retina detachment/di [Diagnosis]
  • retina detachment/ep [Epidemiology]
  • retina detachment/et [Etiology]
  • retina detachment/si [Side Effect]
  • retina macula age related degeneration/dt [Drug Th
  • retina tear
  • retina tear/di [Diagnosis]
  • retina tear/ep [Epidemiology]
  • retina tear/et [Etiology]
  • retina tear/si [Side Effect]
  • retrospective study
  • review
  • risk
  • statistics
  • temazepam
  • uveitis
  • uveitis/di [Diagnosis]
  • uveitis/ep [Epidemiology]
  • uveitis/si [Side Effect]
  • vasculotropin XT - endophthalmitis / side effect
  • vitreous hemorrhage
  • vitreous hemorrhage/di [Diagnosis]
  • vitreous hemorrhage/ep [Epidemiology]
  • vitreous hemorrhage/et [Etiology]
  • vitreous hemorrhage/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Day S.

  • Acquah K.

  • Mruthyunjaya P.

  • Grossman D.S.

  • Lee P.P.

  • Shelley Day

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free